Introduction
============

Protein tyrosine phosphatases (PTPases) are expressed in insulin-sensitive tissues (such as liver, muscle and adipose tissue) and have a key role in the regulation of insulin signal transduction pathway \[[@B1-molecules-14-00266]\]. PTP1B, one of the PTPases, is known to be a negative regulator of insulin signal transduction by dephosphorylating the insulin receptor (IR) as well as its substrate, insulin receptor substrates \[[@B2-molecules-14-00266],[@B3-molecules-14-00266]\]. Consequently, the PTP1B inhibitors are recognized as potential therapeutic agents for the treatment of type II diabetes and obesity \[[@B4-molecules-14-00266]\]. As part of our ongoing study to search for new types of PTP1B inhibitors, we found out that a MeOH extract of the roots of *Saussurea lappa* C.B.Clarke (Compositae) inhibited the enzyme activity at a level of 30 μg/mL. The roots of *S. lappa* have been traditionally used as an ethnomedicine to treat gastric pain, abdominal pain, distension, lack of appetite, anorexia, nausea and vomiting \[[@B5-molecules-14-00266], [@B6-molecules-14-00266]\]. Sesquiterpenes, triterpenes, alkaloids, lignans, and tannins have been reported as constituents of this species \[[@B7-molecules-14-00266],[@B8-molecules-14-00266],[@B9-molecules-14-00266],[@B10-molecules-14-00266],[@B11-molecules-14-00266],[@B12-molecules-14-00266],[@B13-molecules-14-00266]\]. Pharmacological studies on the plant revealed that it has anti-ulcer \[[@B8-molecules-14-00266], [@B9-molecules-14-00266]\], anti-carcinogenesis \[[@B10-molecules-14-00266], [@B11-molecules-14-00266]\], and vasorelaxant effects \[[@B12-molecules-14-00266]\], and inhibit nitric oxide (NO) production in lipopolysaccharide (LPS)-activated mouse model \[[@B13-molecules-14-00266]\]. We also reported that some of the isolates from *S. lappa* inhibited the 3-isobutyl-1-methylxanthine (IBMX)-induced melanogenesis in B-16 mouse melanoma cells \[[@B7-molecules-14-00266]\]. Interestingly, there was a report on the isolation of PTP1B inhibitory constituents from *S. lappa*, and Li *et al*. reported that anthraquinones isolated from its roots had moderate PTP1B inhibitory activities \[[@B14-molecules-14-00266]\]. However, in our current investigation, we found out that betulinic acid (**1**) and its methyl ester **2**, as well as two guaiane sesquiterpenoids, mokko lactone (**3**) and dehydrocostuslactone (**4**), had a high PTP1B inhibitory activity. In this paper, we describe the bioassay-guided isolation of active compounds, and their PTP1B inhibitory activity.

Results and Discussion
======================

Through bioassay-guided fractionation of a MeOH extract of the roots of *S. lappa* 13 compounds were obtained. All the compounds isolated were identified as known constituents of this species \[[@B7-molecules-14-00266]\]. The assay for PTP1B inhibitory activity of all of them, as shown in [table 1](#molecules-14-00266-t001){ref-type="table"}, revealed that the compounds **1**, **2**, **3**, and **4** inhibited PTP1B activity with 0.70 ± 0.03, 0.93 ± 0.07, 1.41 ± 0.02, and 6.51 ± 0.64 μg/mL, respectively. In particular, betulinic acid (**1**) and its methyl ester **2** displayed the highest activity, which was comparable to those of ursolic acid and RK-682 used as positive controls. However, compounds **5** **--** **13** did not show PTP1B inhibitory activity in our enzyme assay system (less than 50% inhibition at the level of 30 μg/mL). Only two guaiane-type sesquiterpenoids showed the PTP1B inhibitory activity, while eudesmane-type and germacrane-type sesquiterpenoids appeared to be inactive.

Recently, betulinic acid isolated from *Alnus hirsuta* Ruprecht was demonstrated to inhibit diacylglycerol acyltransferase (DGAT) activity so that it was proposed as a lead moiety for the development of drug for metabolic diseases such as diabetes and obesity \[[@B15-molecules-14-00266]\]. In addition, guaiane sesquiterpenoids, zaluzanin c and 9α-hydroxyguaian-4(15),10(14),11(13)-triene-6,12-olide, isolated from the roots of *Ixeris dentata* forma *albiflora* Nakai were reported to have DGAT inhibitory activity \[[@B16-molecules-14-00266]\]. Although betulinic acid is a common compound widely distributed in many plant species, it attracts our attention because of its various biological activities \[[@B17-molecules-14-00266]\]. On the basis of our findings, we suggest that betulinic acid derivatives and guaiane sesquiterpenoids are capable of inhibiting PTP1B activity. These-type molecules are known to be favorable to cellular penetration, which increase the potential use in the development of new PTP1B inhibitors, as the target is intracellular.

![Chemical structures of compounds isolated from the roots of *S. lappa.*](molecules-14-00266-g001){#molecules-14-00266-f001}
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PTP1B inhibitory activity of compounds **1** -- **13** isolated from the roots of *S. lappa*

  Compound                              Inhibition*^a^* %   IC~50~ (μg/mL)
  ------------------------------------- ------------------- ----------------
  MeOH extract                          61.0                
  EtOAc fraction                        84.0                
  H~2~O fraction                        22.3                
  Betulinic acid (**1**)                95.1                0.7 ± 0.03
  Betulinic acid methyl ester (**2**)   89.4                0.9 ± 0.07
  Mokko lactone (**3**)                 93.1                1.4 ± 0.02
  Dehydrocostuslactone (**4**)          86.2                6.5 ± 0.64
  Costunolide (**5**)                   \< 50.0             na*^b^*
  11β,13-Dihydrocostunolide (**6**)     \< 50.0             na
  Reynosin (**7**)                      \< 50.0             na
  1β-Hydroxy arbusculin A (**8**)       \< 50.0             na
  Santamarine (**9**)                   \< 50.0             na
  α-Costol (**10**)                     \< 50.0             na
  β-Sitosterol (**11**)                 \< 50.0             na
  Aplotaxene (**12**)                   \< 50.0             na
  α-Amyrin stearate (**13**)            \< 50.0             na
  Ursolic acid*^c^*                     99.0                0.7 ± 0.05
  RK-682*^c^*                           98.5                1.2 ± 0.09

*^a^* Inhibition (%) of PTP1B activity at 30 μg/mL; *^b^* na: not active (less than 50% inhibition at the level of 30 μg/mL); *^c^* Positive controls

Experimental
============

General
-------

Optical rotations were measured using a JASCO DIP-1000 (Tokyo, Japan) automatic digital polarimeter. The FT-IR spectra were recorded on a JASCO FT-IR 300E spectrophotometer, and UV spectra on a JASCO V-550 spectrophotometer. The NMR spectra were recorded on Bruker 250 MHz (DMX 250) spectrometer, using Bruker\'s standard pulse program, with chemical shifts reported in ppm downfield from TMS. The EI-MS spectra were recorded on a Micromass spectrum (AUTOSPEC, UK). Column chromatography was carried out on Merck silica gel (70-230 mesh, Merck), MCI-gel CHP-20P (75-150 μm, Mitsubishi Chem. Co.) and Merck Lichroprep RP-18 gel (40-63 μm). TLC was performed on aluminum plates precoated with Kieselgel 60 F~254~ (Merck). All other chemicals and solvents were of analytical grade.

Plant material
--------------

Dried roots of *S. lappa* (Compositae) were purchased in March 2006 from a folk medicine market ("Yak-ryong-si") in Daegu, Korea, and identified by Prof. See Ryun Chung (Yeungnam University, Korea). A voucher specimen (SH006-179) has been deposited at the College of Pharmacy, Yeungnam University, Korea.

Bioassay-guided fractionation of the MeOH extract
-------------------------------------------------

The roots of *S. lappa* were extracted three times with MeOH at room temperature for seven days. The MeOH extract that showed about 61% PTP1B inhibitory activity at 30 μg/mL was suspended in water and partitioned with EtOAc, and the EtOAc-soluble fraction displayed higher activity (about 84% inhibitory activity at 30 μg/mL) than that of original extract. From the EtOAc-soluble fraction, 13 subfractions (SEfr. 1 \~ 13) were obtained by silica gel chromatography eluting with a CH~2~Cl~2~-MeOH gradient from 100:0 to 0:100. Of the fractions obtained, SEfr. 4, 5, 6, and 7 showed strong PTP1B inhibitory activity (over than 80% inhibition at 30 μg/mL). In particular, SEfr. 7 showed the most potent activity (95% inhibition at 30 μg/mL), which led us to investigate its active constituents preferentially. Fraction SEfr. 7 (15.4 g) was loaded onto a silica gel column (70 × 6 cm) and eluted with a *n*-hexane-EtOAc gradient (100:0, 95:5, 90:10, 85:15, 80:20, 70:30, 60:40, 40:60, 20:80, 0:100), and yielded another 13 subfractions (SEfr. 7-1 \~ 7-13). Silica gel column chromatography of SEfr. 7-4 and 7-5 that showed the highest activity (over than 90% inhibition at 15 μg/mL) led to the isolation of betulinic acid (**1**) \[[@B18-molecules-14-00266]\] and betulinic acid methyl ester (**2**) \[[@B19-molecules-14-00266]\] as active principles. Since betulinic acid (**1**) and its methyl ester **2** were detected in the fractions SEfr. 6, the activity of SEfr. 6 was regarded as the effect of compounds **1** and **2**. We tried to purify other active constituents from SEfr. 4 and 5. Column chromatography of SEfr. 4 (8.6 g) on a silica gel column (60 × 4.6 cm) using a gradient of *n*-hexane-EtOAc (100:0, 98:2, 96:4, 95:5, 92:8, 75:15, 70:30, 50:50, 30:70, 0:100) resulted in the purification of 1β-hydroxy arbusculin A (**8**, 28 mg) \[[@B20-molecules-14-00266]\], dehydrocostuslactone (**4**, 1.6 g) \[[@B21-molecules-14-00266]\], costunolide (**5**, 368 mg) \[[@B22-molecules-14-00266]\], 11β,13-dihydrocostunolide (**6**, 49 mg) \[[@B23-molecules-14-00266]\], and reynosin (**7**, 20 mg) \[[@B24-molecules-14-00266]\]. SEfr. 5 (5 g) was also separated by MCI-gel CHP-20P column (60 × 5 cm) using a stepwise gradient of MeOH-H~2~O (10:90, 30:70, 50:50, 60:40, 70:30, 75:25, 90:10, 100:0), to give 12 fractions (SEfr. 5-1 \~ 5-12). Mokko lactone (**3**, 78 mg) \[[@B25-molecules-14-00266]\] and α-costol (**10**, 87 mg) \[[@B26-molecules-14-00266]\] were finally isolated from SEfr. 5-10 (1.0 g) through a silica gel column chromatography (50 × 4.3 cm) using *n*-hexane-CH~2~Cl~2~-EtOAc gradient system (20:0:0, 14:6:0, 14:6:0.5, 14:6:1, 14:6:2). Four other known compounds, santamarine (**9**) \[[@B24-molecules-14-00266]\], β-sitosterol (**11**) \[[@B7-molecules-14-00266]\], aplotaxene (**12**) \[[@B7-molecules-14-00266]\], and α-amyrin stearate (**13**) \[[@B7-molecules-14-00266]\] were also isolated during the purification process. The structures of compounds isolated ([Figure 1](#molecules-14-00266-f001){ref-type="fig"}) were determined by MS and NMR analysis, and confirmed by comparison of the spectroscopic data with those in literature \[[@B7-molecules-14-00266]\].

Assay method of PTP1B inhibitory activity
-----------------------------------------

PTP1B (human, recombinant) was purchased from BIOMOL® International LP (Plymouth Meeting, PA). The enzyme activity was measured using *p*-nitrophenyl phosphate (*p*NPP) as a substrate \[[@B27-molecules-14-00266]\]. To each of 96 wells in a microtiter plate (final volume: 100 μL) was added 2 mM *p*NPP and PTP1B (0.05-0.1 μg) in a buffer containing 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA, and 1 mM dithiothreitol (DTT) with or without test compounds. Following incubation at 37°C for 30 min, the reaction was terminated with 10 M NaOH. The amount of produced *p*-nitrophenol was estimated by measuring the absorbance at 405 nm. The non-enzymatic hydrolysis of 2 mM *p*NPP was corrected by measuring the increase in absorbance at 405 nm obtained in the absence of PTP1B enzyme.
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*Sample Availability:* Samples of the compounds **1** - **5**, **8 - 10**, and **13** are available from authors
